Total and low-density lipoprotein cholesterol in high-risk patients treated with atorvastatin monotherapy in the United Kingdom: analysis of a primary-care database

Abstract Objective: British clinical guidelines recommend statins as first-line lipid-modifying treatment (LMT) for patients at high risk of cardiovascular disease (CVD). We undertook an observational study to assess total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels in hi...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2014-04, Vol.30 (4), p.655-665
Main Authors: Jameson, Kevin, Zhang, Qiaoyi, Zhao, Changgeng, Ramey, Dena Rosen, Tershakovec, Andrew M., Gutkin, Stephen W., Marrett, Elizabeth
Format: Article
Language:English
Subjects:
Aged
Atherosclerosis
Atherosclerosis (general aspects, experimental research)
Atorvastatin Calcium
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Cardiovascular disease
Cholesterol
Cholesterol - blood
Cholesterol, LDL - blood
Diabetes
Diabetes. Impaired glucose tolerance
Drug therapy
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Female
Heptanoic Acids - therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Primary Health Care
Pyrroles - therapeutic use
Retrospective Studies
Statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective: British clinical guidelines recommend statins as first-line lipid-modifying treatment (LMT) for patients at high risk of cardiovascular disease (CVD). We undertook an observational study to assess total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels in high-risk patients who were treated with atorvastatin monotherapy by UK general practitioners. Methods: This retrospective database study included patients with a prescription for atorvastatin monotherapy between November 30, 2008, and November 30, 2011, with the index date defined as the first atorvastatin prescription during this period. Eligible high-risk patients with evidence of coronary heart disease (CHD), atherosclerotic vascular disease (AVD), diabetes mellitus (DM), or familial hypercholesterolemia (FH) were required to have 1 TC and LDL-C measurement between 3 and 12 months after the index date, and continuous enrollment 1 year before and 1 year after the index date. Cholesterol levels were assessed using the National Institute for Health and Care Excellence (NICE) guidelines: TC
ISSN:0300-7995
1473-4877
DOI:10.1185/03007995.2014.890926